Alector, Inc. (NASDAQ:ALEC) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. trimmed its position in Alector, Inc. (NASDAQ:ALEC) by 88.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,100 shares of the company’s stock after selling 629,445 shares during the period. Alliancebernstein L.P. owned about 0.08% of Alector worth $155,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nordea Investment Management AB lifted its holdings in shares of Alector by 5.1% during the 4th quarter. Nordea Investment Management AB now owns 165,713 shares of the company’s stock worth $295,000 after acquiring an additional 7,971 shares during the period. SG Americas Securities LLC increased its position in Alector by 27.9% during the fourth quarter. SG Americas Securities LLC now owns 39,334 shares of the company’s stock worth $74,000 after purchasing an additional 8,581 shares during the last quarter. Vontobel Holding Ltd. raised its stake in Alector by 127.3% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $47,000 after purchasing an additional 14,000 shares during the period. Intech Investment Management LLC boosted its holdings in shares of Alector by 83.5% in the 4th quarter. Intech Investment Management LLC now owns 35,382 shares of the company’s stock valued at $67,000 after purchasing an additional 16,096 shares during the last quarter. Finally, Apollon Wealth Management LLC purchased a new stake in shares of Alector during the 4th quarter valued at $47,000. 85.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ALEC. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Alector in a research report on Thursday, February 27th. Morgan Stanley restated an “underweight” rating and issued a $1.50 price objective (down from $3.00) on shares of Alector in a report on Friday, March 7th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $3.50.

Alector Trading Up 14.0 %

Shares of NASDAQ ALEC opened at $1.11 on Wednesday. The stock has a fifty day moving average price of $1.33 and a 200 day moving average price of $2.43. The company has a market cap of $109.99 million, a P/E ratio of -0.65 and a beta of 0.73. Alector, Inc. has a 12-month low of $0.87 and a 12-month high of $6.78.

Alector (NASDAQ:ALEC) last posted its earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.59. The business had revenue of $54.24 million during the quarter, compared to analyst estimates of $20.41 million. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. On average, sell-side analysts forecast that Alector, Inc. will post -1.88 EPS for the current fiscal year.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.